Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Baka, S. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Papacostas, P. | en |
dc.contributor.author | Boukovinas, I. | en |
dc.contributor.author | Bakoyiannis, Chris | en |
dc.contributor.author | Pantelakos, P. | en |
dc.contributor.author | Athanassiou, E. | en |
dc.contributor.author | Misailidou, D. | en |
dc.contributor.author | Tsekeris, P. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Baka, S. | en |
dc.creator | Samantas, E. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Gogas, H. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Papacostas, P. | en |
dc.creator | Boukovinas, I. | en |
dc.creator | Bakoyiannis, Chris | en |
dc.creator | Pantelakos, P. | en |
dc.creator | Athanassiou, E. | en |
dc.creator | Misailidou, D. | en |
dc.creator | Tsekeris, P. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:48Z | |
dc.date.available | 2018-06-22T09:53:48Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42036 | |
dc.description.abstract | Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy following induction with non-platinum chemotherapy in patients with inoperable locally advanced NSCLC. Patients and Methods: All patients with locally advanced inoperable NSCLC ECOG performance status (PS): 0-1 following staging received paclitaxel 200 mg/m2 in a 3-h infusion on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days for two cycles. The patients with a response or stable disease (SD) continued to receive paclitaxel 60 mg/m2 weekly and radiotherapy 63 Gy given at 1.8 Gy once a day for 7 weeks. Results: Forty-three eligible patients entered the study. The median age was 63 years (range 42-76), male 93%, IIIB 63% and IIIA 37%. Following induction 15 (36.5%) of the patients responded: complete response (CR), 2%; partial response (PR), 33%; and 19 (46.5%) SD. From those with SD, 7 (37%) improved to a PR following concurrent chemoradiotherapy. With a median follow-up of 44 months (95% CI: range 36-53) the median survival was 20.8 months (95%c CI: range 15.4-26.3) and time-to-progression 8.4 months (95% CI: range 6.2-10.6). The median survival of those who had improved response from SD to PR was 31.4 months (95% CI: range 18.7-44.1) versus 20.8 months (95% CI: range 5.5-11.3) for those who had no improvement (p=0.20). The commonest grade 3/4 toxicity in induction was neutropenia 12% with 2 febrile neutropenic patients whereas in the concurrent chemoradiotherapy neutropenia, neurotoxicity and oesophagitis were observed in 6% of the patients. Conclusion: Concurrent chemoradiotherapy following induction chemotherapy in patients with stage III NSCLC is feasible with reasonable efficacy and acceptable toxicity. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Follow up | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug safety | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Cancer staging | en |
dc.subject | Patient compliance | en |
dc.subject | Survival rate | en |
dc.subject | Treatment outcome | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Carcinoma | en |
dc.subject | Disease course | en |
dc.subject | Male | en |
dc.subject | Radiotherapy | en |
dc.subject | Survival time | en |
dc.subject | Disease severity | en |
dc.subject | Treatment response | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Esophagitis | en |
dc.subject | Combination chemotherapy | en |
dc.subject | Deoxycytidine | en |
dc.subject | Gemcitabine | en |
dc.subject | Paclitaxel | en |
dc.subject | Combined modality therapy | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Treatment indication | en |
dc.subject | Radiation dose | en |
dc.subject | Concurrent chemoradiotherapy | en |
dc.subject | Kaplan-meiers estimate | en |
dc.subject | Non-operable localized nsclc | en |
dc.title | Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 27 | |
dc.description.issue | 6 C | en |
dc.description.startingpage | 4391 | |
dc.description.endingpage | 4395 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |